Suzhou Baimai Biopharmaceutical Co.
Latest round
- Series A
Last raised
- Sep 2022
Total raised
- $7.4M
Investors
- 2
About Suzhou Baimai Biopharmaceutical Co.
, Ltd. is a pharmaceutical company focusing on the platform of biomaterial technology. Currently, it has realized the Lincese out business cooperation of an early product and has a self-initiated pipeline, BM201, approved for IND and about to enter Phase I clinical. The founder Zhuang Liu has been working in the field of biomaterials for more than ten years. The company focuses on innovative drugs and agents for the treatment of diseases such as oncology and cancer and provides immunotherapy treatment options. The development pipeline includes the long-acting extended-release formulation BM201, the ICD-chemical combination formulations BM101 and BM221, and the multichannel immune agonist BM501.
Who invested in Suzhou Baimai Biopharmaceutical Co.
2 investors across 2 rounds
See all investors in Suzhou Baimai Biopharmaceutical Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Suzhou Baimai Biopharmaceutical Co.
Who invested in Suzhou Baimai Biopharmaceutical Co.?
Suzhou Baimai Biopharmaceutical Co. has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Suzhou Baimai Biopharmaceutical Co. raised?
Suzhou Baimai Biopharmaceutical Co. has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Suzhou Baimai Biopharmaceutical Co. last raise money?
Suzhou Baimai Biopharmaceutical Co.'s most recent round on record is a Series A, in Sep 2022.
What does Suzhou Baimai Biopharmaceutical Co. do?
Suzhou Baimai Biopharmaceutical Co. is a biotechnology company.
Where is Suzhou Baimai Biopharmaceutical Co. headquartered?
Suzhou Baimai Biopharmaceutical Co. is headquartered in Suzhou, China.
Which VCs invest in companies like Suzhou Baimai Biopharmaceutical Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Suzhou Baimai Biopharmaceutical Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Suzhou Baimai Biopharmaceutical Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.